Efficacy and Safety of Tofacitinib in Patients With COVID-19 Pneumonia
Status:
Completed
Trial end date:
2020-09-01
Target enrollment:
Participant gender:
Summary
TOFA-COV-2 is a cohort study of the efficacy of tofacitinib in reducing the risk of
mechanical ventilation and/or death in patients with moderately severe COVID-19 pneumonia who
received standard of care treatment (SoC). The study population consists of adults (≥18
years) with COVID-19, who are admitted to the university hospitals and don't require invasive
or noninvasive ventilation on admission. All patients are divided into four groups depending
on nadir levels of oxygen saturation and therapy: (1) patients with oxygen saturation ≤93%
who received tofacitinib and SoC, (2) patients with oxygen saturation ≤93% who received only
SoC, (3) patients with oxygen saturation >93% who received tofacitinib and SoC, (4) patients
with oxygen saturation >93% who received only SoC. The aim of the study is to test the
hypothesis that addition of tofacitinib to SoC could reduce the risk of mechanical
ventilation and/or death.
Phase:
Phase 2
Details
Lead Sponsor:
I.M. Sechenov First Moscow State Medical University